The SCLC CDX model we used to study sGCs and acquired resistance to SCLC standard of care chemotherapy in vivo, CDX17P, showed upregulation of MYC compared to this donor’s baseline model CDX1710. Here, MYC is linked to small cell lung carcinoma.